Dr. Neil Singla, Chief Executive Officer of Lotus Clinical Research, will discuss ‘Opioid Sparing Outcomes: Practical Perspectives from 20 Years of Acute Pain Clinical Trials’ at the 19th Annual Pain Therapeutics Conference, taking place in London, UK on May 13-14, 2019.
PASADENA, CA January 25, 2019
“There is significant commercial and societal demand for opioid-sparing medications that could provide relief from opioid-related side effects; however, due to a lack of validated measurements and inadequate study powering, drug developers have yet to meet the rigorous evidence standards required to secure a complete opioid-sparing label claim,” said Dr. Neil Singla, Chief Executive Officer of Lotus Clinical Research.
“The global opioids market size was valued at $22.96bn USD in 2016 and is projected to expand at a CAGR of 4.8% between 2018 and 2025. Rising prevalence of diseases that cause chronic pain, such as cancer, lower back pain, postsurgical pain, arthritis, and fibromyalgia, is driving growth.” – SMi Pain Therapeutics
Dr. Singla will discuss an overview of the strengths and weaknesses of current opioid-sparing outcomes, outline clinical trial design concerns in opioid-sparing studies, and discuss the potential utility of a new study endpoint: proportion of opioid-free patients at the 19th Annual Pain Therapeutics Conference, taking place in London, UK on May 13-14, 2019. For more information, please visit: https://www.smi-online.co.uk/pharmaceuticals/uk/pain-therapeutics.
Lotus Clinical Research, a specialty analgesic CRO and research site, has performed more than 350 analgesic clinical trials, as well as guided several analgesic agents through FDA approval. For more information on the services provided by Lotus Clinical Research, please visit: http://www.lotuscr.com/.
“SMi’s Pain Therapeutics Conference will explore the cutting-edge research of novel therapeutic targets in the pipeline of leading pharmaceutical companies and to discuss solutions for the challenges of clinical trial design and conduct. This conference will cover the leading advances in pain therapeutics, exploring late development clinical trials and bridging the gap from labs to shelf, ion channels as analgesic drug targets, migraine treatments, such as Lasmiditan and Aimovig, novel discoveries in opioid-free analgesia and the future forecast for pain therapeutics. Furthermore, the two-day agenda for the conference will be full of insightful presentations from key industry leaders introducing new case studies as well as policy experts providing essential regulatory perspectives. This will bring together the challenges and successes of both pre-clinical and clinical development to equip attendees with the necessary knowledge to advance the pain therapeutic industry.” – SMi Pain Therapeutics
Please visit https://www.smi-online.co.uk/pharmaceuticals/uk/pain-therapeutics for registration information.